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Poster Session-I 87had AML: 6 induction failures, 6 in refractory relapse, 3 in untreated
relapse, 1 had a second PR, 1 chemo-responsive MDS, 1 in high-risk
CR1 [cytogenetics (CG) -7/t(3;12)]. CG were favorable (n5 1), 8 in-
termediate, and 6 poor prognosis, and in 3 CG were unknown.
GVHD-prophylaxis: tacrolimus/mini-MTX, with rabbit-ATG
(Thymoglobulin) for unrelated/one Ag-mism. related donor trans-
plants.
Results: 1 patient died of pneumonia (day177), and 1 of liver
GVHD (day145) as only treatment-related deaths in the 1st 100
days. Main toxicity was mucositis grade 2–3 (50% of the pts). There
was no significant hepatic/neurologic toxicity. All 22 evaluable pts
engrafted (one progressed by day 130). T-cell chimerism studies
at day130 revealed that groups I1II (lower Clo doses; n 5 10)
had a median of 87% (17–100) donor (T-cell)-derived DNA, groups
III1IV (higher Clo-doses, n5 12) had a median of 100% range (64–
100) donor-DNA. By day1100 both cohorts had a median of 100%
donor-derived DNA, maintained beyond 6 mo. in all evaluable pts. 3
pts are too early; 10 pts have died: PD (5), GVHD 6 infection (4),
and pneumonia (1); 1 AML patient is alive after recurrence and 7
AML and 4 CML patients are alive in CR at a median F/up of 9
mos (4–21).
Conclusions: 1) Clo-Bu-based conditioning appears safe in high-
risk ML pts. 2) there should be no concern about the immunosup-
pressive capability of Clo in this setting 3) additional studies are war-
ranted to evaluate the antileukemic efficacy of this regimen.
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Non-neutropenic
diet P
Age (years) 57 (18–76) 56 (18–78) 0.89
Male:Female 186:128 190:124 0.97
Allogeneic:Autologous 77:237 72:242 0.64
Diagnosis 0.91
Myeloma 163 165
NHL 57 64
AML 54 50
Other 40 39
Conditioning regimen 0.97
High-dose Melphalan 163 165
BEAM 45 42
Busulfan-fludarabine 32 33
Reduced-intensity 33 36
Median days to neutrophil
recovery
12 12 0.91
Positive cultures during
neutropenia
97 89 0.49
CoNS/MSSA/MRSA 1
miscellaneous gram-positive
32 33 1
C difficile 24 22 0.88
E faecium (VRE) 9 9 1
Non-VRE Enterococci 3 3 1
Gram-negative bacilli 15 9 0.21
S viridans 11 10 1
Fungus 4 3 1
Positive cultures after
resolution of neutropenia
48 20 \0.001
CoNS/MSSA/MRSA 1
miscellaneous gram-positive
21 9 0.028
C difficile 9 2 0.069
E faecium (VRE) 7 3 0.34
Gram-negative bacilli 8 4 0.38
S viridans 2 1 1
Fungus 1 1 1
VRE surveillance culture
positivity acquired during
hospitalization
56 31 \0.004SUPPORTIVE CARE
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A RANDOMIZED, CONTROLLED TRIAL OF GRAFT-VERSUS-HOST DISEASE
(GVHD) PROPHYLAXIS COMPARING TACROLIMUS AND MYCOPHENO-
LATE MOFETIL TO TACROLIMUS AND METHOTREXATE: ANALYSIS OF
GVHD, RELAPSE AND SURVIVAL
Perkins, J.1, Alsina, M.1, Anasetti, C.1, Ayala, E.1, Fernandez, H.1,
Kharfan-Dabaja, M.1, Ochoa-Bayona, L.1, Perez, L.1,
Raychaudhuri, J.1, Sullivan, D.1, Kim, J.2, Schell, M.2, Field, T.1 1Mof-
fitt Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL
We conducted a single institution, randomized, controlled trial
comparing tacrolimus 1 MTX (TAC/MTX) to tacrolimus 1
MMF (TAC/MMF). Eligible patients (pts) were to receive T-replete
peripheral blood HCT from 10/10 or 9/10 HLA matched donors.
Randomization was stratified based on conditioning regimen inten-
sity. 92 pts were randomized, 45 to TAC/MMF and 47 to TAC/
MTX and were all included in the intent-to-treat (ITT) analysis.
Two pts were not transplanted and one pt withdrew consent prior
to transplant. These pts were excluded in the modified ITT
(MITT) analysis. Pts received TAC 0.03 mg/kg/24hr as a continuous
IV infusion beginning day -3 with doses adjusted to maintain whole
blood levels of 5–15ng/ml. Pts were converted to PO therapy and ta-
pered after 6 months. MTX was given IV at doses of 15mg/m2 day
11 and 10mg/m2 on days 13, 16 and 111. MMF was dosed at 15
mg/kg every 12 hours (up to 3g/d) IV beginning day 0, switched to
PO and continued for 12 months. Acute GVHD (aGVHD) was
graded weekly by standard criteria; chronic GVHD (cGVHD) was
scored monthly based on NIH consensus criteria. The groups
were balanced with respect to age, diagnosis, disease risk, recipi-
ent/donor CMV status, conditioning regimen, donor type and rela-
tion. The cumulative incidences of grade 2–4 and 3–4 aGVHD were
79% and 4% in the TAC/MTX arm and 76% and 14% in the TAC/
MMF arm (MITT; p 5 0.84 and 0.1, respectively). The cumulative
incidence of moderate or severe cGVHD at 6 months was 22% in the
TAC/MTX arm and 26% in the TAC/MMF arm (MITT; p5 0.88).
By ITT analysis, the cumulative incidence of non-relapse mortality
suggested an early difference in favor of TAC/MTX, but at 2 years
it was 28% for TAC/MTX arm compared to 32% for the TAC/
MMF arm (p 5 0.41). The cumulative incidence of relapse was
33% in TAC/MTX arm compared to 18% for the TAC/MMF pts
(p 5 0.06). Overall survival was similar between groups (p 5 0.76;
62% TAC/MTX vs. 66% TAC/MMF at 1 year). We conclude
that MMF was no better than MTX in preventing GVHD and
may perhaps be less effective in preventing more severe forms ofaGVHD. Given the direction of effect we observed in severe
aGVHD, it is unlikely that a larger trial would show benefit for
this endpoint. There was a strong suggestion that relapse was
more frequent after MTX than MMF. The beneficial effect of
MMF on relapse was offset by the early increase in nonrelapse mor-
tality, so that overall survival was unaffected.240
QUESTIONING THE ROLE OF A NEUTROPENIC DIET IN HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Trifilio, S., Pi, J., Holmes Gobel, B., Giel, M., Fishman, M., Masino, K.,
Lucier, E., Korenaga, Y., Mehta, J. Northwestern Memorial Hospital,
Chicago, IL
Neutropenic diets (ND) were developed to decrease gut-derived
infections and are widely used. After finding that there were no clin-
ical trials supporting their use, we discontinued ND in HSCT in late
2006. Our ND excluded fresh fruits and vegetables as well as black
pepper, sushi, deli meats, raw milk products, soft cheeses, raw honey,
miso, and yeast. It was replaced by a modified general diet (Non-
ND) that permits black pepper, fresh fruits and vegetables, and
homemade freshly squeezed juice - but excludes raw tomatoes.
The other restrictions remain. 648 consecutive hospitalized patients
were studied; 314 on ND and 314 after ND discontinuation (non-
ND). All infections occurring during the first hospital stay were
analyzed. All patients received ciprofloxacin 500 mg twice a day,
fluconazole 200 mg daily (autograft) or voriconazole 200 mg twice
daily (allograft), and acyclovir/valacyclovir. The documented infec-
tions included in the analysis comprised positive blood, urine
(.100,000 organisms), BAL, stool, or wound cultures, and clostrid-
ium difficile. As the table shows, there were no differences between
